-
My Account
In App
My Account
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 1 | 1895.00 | 1899.00 | 2 |
| 55 | 1888.95 | 1899.15 | 126 |
| 20 | 1888.40 | 1899.25 | 126 |
| 20 | 1888.15 | 1899.50 | 70 |
| 19 | 1888.05 | 1899.80 | 101 |
| 0 | Total | Total | 0 |
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 1 | 1895.00 | 1899.00 | 2 |
| 55 | 1888.95 | 1899.15 | 126 |
| 20 | 1888.40 | 1899.25 | 126 |
| 20 | 1888.15 | 1899.50 | 70 |
| 19 | 1888.05 | 1899.80 | 101 |
| 0 | Total | Total | 0 |
As on --
(OI , PRICE )
As on --
| Open | 1,889.10 |
| Previous Close | 1,891.20 |
| Volume | 521,647.00 |
| Value (Lacs) | 9,902.95 |
| VWAP | 0.00 |
| Beta | |
| Mkt Cap (Rs. Cr.) | 53,573 |
| High | 1,919.00 |
| Low | 1,885.20 |
| UC Limit | 0.00 |
| LC Limit | 0.00 |
| 52 Week High | 2,284.80 |
| 52 Week Low | 1,275.50 |
| Face Value | 1.00 |
| All Time High | 2,284.80 |
| All Time Low | 18.75 |
| 20D Avg Volume | 577,321 |
| 20D Avg Delivery(%) | 58.71 |
| Book Value Per Share | 313.59 |
| Dividend Yield | 0.13 |
| TTM EPS See historical trend | 26.71 (+157.48% YoY) |
| TTM PE See historical trend | 71.07 (High PE) |
| P/B See historical trend | 6.05 (High P/B) |
| Sector PE | 40.00 |
*Delayed by 20 seconds.
Stock Score
Get detailed analysis with Moneycontrol Stock Insights.
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| Days | |
|---|---|
| 5 | - - |
| 10 | - - |
| 20 | - - |
| 50 | - - |
| 100 | - - |
| 200 | - - |
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| Days |
|---|
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| Days |
|---|
| 1 Week | --% | |
| 1 Month | --% | |
| 3 Months | --% | |
| YTD | --% | |
| 1 Year | --% | |
| 3 Years | --% |
11 out of 17 years Glenmark Pharma has given positive returns in November.
| Month | Max. Positive Change(%) | Avg. Positive Change(%) | Max. Negative Change(%) | Avg. Negative Change(%) | Average Change(%) |
|---|---|---|---|---|---|
| November | 14.14% (2014) | 4.68% | -9.79% (2024) | -5.84% | 0.97% |
Glenmark signs cancer drug licensing deal with China's Hengrui for $18 million upfront with $1.1 billion in milestone payments Sep 24 2025 05:49 PM
CRISIL raises Glenmark Pharma's outlook to 'Positive', reaffirms ratings Sep 19 2025 10:59 AM
Glenmark Pharma shares rise 2.08% on price increase Sep 18 2025 11:08 AM
Glenmark Pharma share price falls 2.18% amid price fall Sep 11 2025 10:07 AM
Posted by : The Fixed Income
Repost this message
Steady Returns Backed by the State of Maharashtra ✔️ Coupon: 8.42% ✔️ Tenor: 2y 8m (Maturity: 01/Aug/2028) G-Sec | Listed | Sovereign-Backed Enjoy peace of mind with a state-backed investment that offers assured returns and low risk — the perfect mix of stability and steady income for your portfolio. ???? Explore on The Fixed Income: https://www.thefixedincome.com/product/dVJhc1p3PT0=/842-maharashtra-sdl-2028?utm_source=Moneycontrol&utm_medium=Forum&utm_campaign=Product_list
| Qty 264465 | Price 1492.65 | % Traded 0.09 |
| Qty 264465 | Price 1492.65 | % Traded 0.09 |
| Qty 671394 | Price 1510 | % Traded 0.24 |
| Qty 671394 | Price 1510 | % Traded 0.24 |
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
| Qty 1510591 | Price 2171.67 | % Traded 0.53 |
| Qty 1510591 | Price 2173.31 | % Traded 0.53 |
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
| Date | Agenda |
|---|
| Ex-Date | Type | Dividend (Rs) |
|---|
| Announcement Date | Ex-Bonus | Ratio |
|---|
| Ex-Split | Old FV | New FV |
|---|
| Ex-Right | Ratio | Premium |
|---|
| Date | Agenda |
|---|
| Company Name | Price | % Chg | MCap(Cr) | TTM PE | P/B | ROE(%) | 1 Yr Perform(%) | Net Profit(Rs.) | Net Sales(Rs.) | Debt to Equity |
|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark | 1,898.40 | 0.38 | 53,573.00 | 71.07 | 6.05 | 11.83 | 12.31 | 1,047 | 13,321 | 0.25 |
| Sun Pharma | 1,706.40 | 0.93 | 409,422.52 | 39.47 | 5.67 | 15.13 | -8.18 | 10,980 | 52,578 | 0.03 |
| Divis Labs | 6,804.00 | 0.98 | 180,624.82 | 78.32 | 12.07 | 14.63 | 15.25 | 2,191 | 9,360 | 0.00 |
| Torrent Pharma | 3,628.30 | 1.92 | 122,798.16 | 61.34 | 16.36 | 25.17 | 13.20 | 1,911 | 11,516 | 0.40 |
| Cipla | 1,511.50 | 0.68 | 122,094.62 | 22.44 | 3.91 | 16.90 | -3.08 | 5,291 | 27,547 | 0.00 |
Sharpest Opinions & Actionable Insights 
Exclusive Webinars 
Research & Expert Technical Analysis 
